Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,547,616 papers from all fields of science
Search
Sign In
Create Free Account
GI 147211
Known as:
GI-147211
, GI147211
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
OSI 211
Broader (1)
lurtotecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
G. Dark
,
A. Calvert
,
+15 authors
E. Eisenhauer
Journal of clinical oncology : official journal…
2005
Corpus ID: 23300279
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan…
Expand
Review
1998
Review
1998
Clinical applications of the camptothecins.
C. Takimoto
,
J. Wright
,
S. Arbuck
Biochimica et biophysica acta
1998
Corpus ID: 8738651
Highly Cited
1998
Highly Cited
1998
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
E. Kumazawa
,
T. Jimbo
,
Y. Ochi
,
A. Tohgo
Cancer Chemotherapy and Pharmacology
1998
Corpus ID: 7830380
Purpose: We have previously reported that DX-8951f, a water-soluble and nonprodrug camptothecin (CPT) derivative, exhibits both…
Expand
1998
1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
S. Eckhardt
,
S. Baker
,
+16 authors
E. Rowinsky
Clinical cancer research : an official journal of…
1998
Corpus ID: 28859453
GI1147211 is a 7-substituted 10,11-ethylenedioxy-20(S)-camptothecin analogue that inhibits the nuclear enzyme topoisomerase I. In…
Expand
1998
1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
L. Paz-Ares
,
R. Kunka
,
+10 authors
P. O'dwyer
British Journal of Cancer
1998
Corpus ID: 5890334
GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was…
Expand
Review
1997
Review
1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
C. Gerrits
,
M. D. de Jonge
,
J. Schellens
,
G. Stoter
,
J. Verweij
British Journal of Cancer
1997
Corpus ID: 15129193
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for…
Expand
Highly Cited
1997
Highly Cited
1997
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
D. L. Warner
,
T. Burke
Journal of chromatography. B, Biomedical sciences…
1997
Corpus ID: 25294680
1997
1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
C. Gerrits
,
J. Schellens
,
+7 authors
J. Verweij
British Journal of Cancer
1997
Corpus ID: 270774
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new…
Expand
1996
1996
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
C. Gerrits
,
G. Creemers
,
+8 authors
J. Verweij
British Journal of Cancer
1996
Corpus ID: 8183979
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with…
Expand
Highly Cited
1995
Highly Cited
1995
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
D. Emerson
,
J. Besterman
,
+7 authors
A. Vuong
Cancer research
1995
Corpus ID: 18874267
The development of camptothecin-like compounds as inhibitors of topoisomerase I for the treatment of resistant tumors has…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE